BOSTON, Sept. 29,
2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.
("NeuroBo") (Nasdaq: NRBO) today announced that on September 27, 2022, NeuroBo received formal
notice from the Listing Qualifications Staff of The Nasdaq Stock
Market LLC indicating that NeuroBo has evidenced full compliance
with the minimum bid price requirement set forth in Nasdaq Listing
Rule 5550(a)(2) and otherwise satisfies all other applicable
criteria for continued listing on The Nasdaq Capital Market. As a
result, the listing matter has been closed.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology
company historically focused on therapies for neurodegenerative and
infectious diseases. On September 14, 2022, NeuroBo entered into a
license agreement with Dong-A ST Co. Ltd. and, if closing
conditions are satisfied and the license agreement closes, NeuroBo
will pursue therapies for cardiometabolic diseases. Its
therapeutics programs currently include ANA001, an oral niclosamide
formulation, which is in Phase 2/3 clinical trials to treat
patients with moderate coronavirus disease (COVID-19); NB-01 for
the treatment of painful diabetic neuropathy; NB-02 for the
treatment of symptoms of cognitive impairment and to modify the
progression of neurodegenerative diseases associated with the
malfunction of tau protein; and gemcabene currently being assessed
as an acute treatment for COVID-19 in combination with ANA001.
NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. For more information,
please visit www.neurobopharma.com.
Forward Looking Statements
Any statements in this press release that are not statements of
historical fact constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements include, but are not limited to,
statements regarding NeuroBo's continued compliance with the Nasdaq
listing rules and the license agreement between NeuroBo and Dong-A
ST Co. Ltd., NeuroBo's ability to meet the conditions to closing of
the license agreement, clinical development activities, the
timeline for, and results of, clinical trials, regulatory
submissions, and potential regulatory approval and
commercialization of its current and future product candidates.
Forward-looking statements are usually identified by the use of
words, such as "believes," "anticipates," "expects," "intends,"
"plans," "may," "potential," "will," "could" and similar
expressions. Actual results may differ materially from those
indicated by forward-looking statements as a result of various
important factors and risks. Please refer to NeuroBo's most recent
annual report on Form 10-K, as well as NeuroBo's subsequent filings
on Form 10-Q and Form 8-K, which are available on the SEC's website
(www.sec.gov), for a full discussion of the risks and other factors
that may impact any forward-looking statements in this press
release. In addition, the forward-looking statements included in
this press release represent NeuroBo's views as of the date hereof.
NeuroBo anticipates that subsequent events and developments will
cause its views to change. However, while NeuroBo may elect to
update these forward-looking statements at some point in the
future, NeuroBo specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing NeuroBo's views as of any date subsequent to the date
Investors & Media:
NeuroBo Pharmaceuticals, Inc.
Rx Communications Group
SOURCE NeuroBo Pharmaceuticals, Inc.